DDInter1782 DDInter1676
Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Racepinephrine
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salmeterol
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentobarbital
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Tetracosactide {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Tetracosactide {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Tetracosactide may lead to a major life threatening interaction when taken with Etanercept
Tetracosactide may lead to a major life threatening interaction when taken with Fingolimod